BioCardia Earnings Call Transcripts
Fiscal Year 2026
-
Positive regulatory progress in Japan and the US positions CardiAMP cell therapy and Helix catheter for potential approvals, with strong financial management extending cash runway into 2027. Japanese market opportunity is significant, supported by favorable reimbursement benchmarks.
-
Barinthus Biotherapeutics is advancing its SNAP-TI platform for autoimmune diseases, with VTP-1000 in phase I for celiac disease and a merger with Clywedog Therapeutics set to add two diabetes assets. Key clinical data are expected in 2024, and the company is funded through 2027.
-
CardiAMP cell therapy achieved key regulatory milestones in Japan and the U.S., with strong clinical data supporting efficacy and safety. Expenses and net loss decreased year-over-year, and the company is preparing for a major market entry in Japan with a $400M opportunity.
Fiscal Year 2025
-
Clinical and financial progress continues, with phase III CardiAMP HF data showing significant benefits in key subgroups and regulatory submissions imminent in the US and Japan. Expenses rose modestly, cash burn remains steady, and multiple near-term catalysts are expected.
-
Regulatory progress continues for cell therapy and delivery platforms, with positive clinical data and advancing trials in heart failure and ischemia. Financials show stable expenses, improved cash position, and a runway into Q2 2026.
-
CardiAMP Heart Failure trial showed positive subgroup results, with regulatory submissions in Japan and the US progressing and key meetings expected in Q4 2025. R&D expenses rose, cash runway extends into October, and a financing event is planned for September.
-
A late-stage cell therapy developer presented positive phase III data for ischemic heart failure, with reduced mortality and improved quality of life, and is advancing regulatory submissions in the U.S. and Japan. Pipeline programs target additional cardiac and pulmonary indications, with active partnership discussions ongoing.
-
Q1 2025 saw increased R&D and total expenses, with a net loss of $2.7M and cash of $949K before a modest financing. CardiAMP and CardiALLO trials advanced, MorphDNA received FDA approval, and business development discussions are active across all platforms.
Fiscal Year 2024
-
CardiAMP Heart Failure Trial data showed strong reductions in cardiac death and adverse events, with significant quality of life improvements in key subgroups, though the primary endpoint was not met. Expenses and net loss declined year-over-year, and regulatory discussions are advancing.
-
Clinical programs advanced with pivotal CardiAmp Heart Failure I data expected Q1 2025 and FDA approval for MorphDNA platform. Expenses and net loss decreased year-over-year, with a $7.2M offering extending cash runway. Personalized trial protocols and business development efforts are accelerating.
-
Q2 2024 saw reduced expenses and net loss, with key clinical milestones approaching for heart failure programs. FDA clearance for Morph DNA is expected soon, and business development efforts are active across all platforms. Funding strategies are in place to maintain Nasdaq compliance.